Upstream Bio to Unveil Refined Efficacy Data for Verekitug in CRSwNP

WALTHAM, Mass. – February 26, 2026 – Upstream Bio is set to present a more detailed look into the efficacy of its investigational drug, verekitug, for chronic rhinosinusitis with nasal polyps (CRSwNP) at the upcoming American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting. The company announced today that new analyses from its positive Phase 2 VIBRANT trial will be featured in a late-breaking poster session on March 1, 2026, in Philadelphia.

This new presentation will focus on the drug's effectiveness after adjusting for the use of concomitant rescue therapies, a statistical method designed to reveal a treatment's true, unconfounded impact. For patients and clinicians grappling with the persistent and debilitating symptoms of CRSwNP—a condition characterized by inflammation of the sinuses and growths known as nasal polyps—this refined data could provide a clearer picture of verekitug's potential as a standalone therapy in a competitive market.

A Deeper Dive into VIBRANT's Efficacy

The VIBRANT trial had already delivered promising news for Upstream Bio in September 2025, when the company reported positive top-line results. The Phase 2 study successfully met its primary endpoint, demonstrating a statistically significant and clinically meaningful reduction in nasal polyp size (measured by endoscopic nasal polyp score, or NPS) at 24 weeks compared to placebo. The initial data showed a placebo-adjusted NPS reduction of -1.8, a result that positions verekitug favorably against other biologics.

Key secondary endpoints were also met, including significant improvements in patient-reported nasal congestion and a reduced need for rescue interventions like systemic corticosteroids or nasal polyp surgery. The drug was reported to be well-tolerated.

The upcoming presentation at AAAAI aims to build upon this foundation by isolating verekitug's effect more precisely. In clinical trials for chronic conditions, patients in both the placebo and treatment arms may use "rescue" medications to manage severe symptom flare-ups. While necessary for patient care, this can muddy the waters when assessing the investigational drug's direct benefit. By statistically adjusting for the use of these rescue therapies, researchers can provide a more accurate measure of the drug's intrinsic efficacy. This analysis is crucial for regulators, payers, and physicians seeking to understand how much of a patient's improvement is directly attributable to the new treatment versus other interventions.

The 'Upstream' Strategy: Targeting the TSLP Receptor

Verekitug's mechanism of action is central to Upstream Bio's corporate strategy and its potential differentiation in the crowded inflammatory disease space. The drug is a monoclonal antibody that targets the thymic stromal lymphopoietin (TSLP) receptor. TSLP is a key epithelial-derived cytokine, often called an "alarmin," that sits at the top of the inflammatory cascade. Released in response to triggers like allergens, viruses, and pollutants, TSLP initiates a broad downstream inflammatory response involving multiple pathways, including the Type 2 inflammation characteristic of CRSwNP and severe asthma.

By blocking the TSLP receptor, verekitug aims to shut down this signaling at a very early stage—an "upstream" approach that the company believes can offer broad and potent anti-inflammatory effects. This strategy has already been validated by the success of Tezspire (tezepelumab), a drug from Amgen and AstraZeneca that targets the TSLP ligand and is approved for both severe asthma and, as of late 2025, CRSwNP.

Upstream Bio contends that its approach is distinct and potentially more powerful. The company highlights that verekitug is the only clinical-stage antagonist targeting the TSLP receptor directly and claims this mechanism makes it significantly more potent than therapies that bind to the TSLP ligand. The success of verekitug in CRSwNP, severe asthma (VALIANT trial), and its ongoing investigation in chronic obstructive pulmonary disease (COPD) (VENTURE trial) are all part of a broader effort to prove the versatility and power of this upstream receptor-blocking strategy across a range of inflammatory conditions.

Navigating a Crowded Market and Investor Scrutiny

The new data from the VIBRANT trial arrives at a critical juncture for Upstream Bio. The market for CRSwNP biologics is increasingly competitive, with established players like Sanofi and Regeneron's Dupixent (dupilumab) and Novartis and Genentech's Xolair (omalizumab), alongside direct TSLP-pathway competitor Tezspire. To succeed, verekitug will need to demonstrate not just efficacy, but a clear and compelling clinical profile that differentiates it from existing options, whether through superior efficacy, a better safety profile, or more convenient dosing.

Investors will be watching the AAAAI presentation closely. While Upstream Bio is well-capitalized, with funds projected to last through 2027, its stock (NASDAQ: UPB) has been volatile since its 2024 IPO. The market's reaction to the company's recent Phase 2 VALIANT trial results in severe asthma was a case in point. Despite the trial meeting its primary endpoint, the stock fell, as investors parsed nuances in the data across different dosing regimens. This suggests a discerning market that demands not just statistical success, but clinically compelling and differentiated outcomes.

Therefore, the upcoming presentation is more than a routine data update. It represents a key strategic opportunity for Upstream Bio to strengthen the clinical narrative for verekitug. A robust demonstration of efficacy, clarified by the adjustment for rescue therapy, could bolster confidence in the drug's potential, inform the design of pivotal Phase 3 trials, and solidify its standing against formidable competitors. The findings presented in Philadelphia will be a significant indicator of verekitug's future trajectory and Upstream Bio's quest to redefine treatment for a host of inflammatory diseases.